Cancer Targeted Therapy

mmu-miR-7658-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

ATR-IN-24 (Compound 1) is a ATR inhibitor. ATR-IN-24 has anticancer activity.

L-Val-D-Cit-PAB is an ADC linker, and can be used for synthesis of ADCs.

PROTAC SOS1 ligand 1, a BI-3406 (HY-125817) analog, is a ligand for target SOS1 protein for PROTACT SIAIS562055 (HY-168637).

Anti-Mouse Fas Ligand Antibody (MFL3) is an anti-mouse Fas Ligand IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse Fas Ligand Antibody (MFL3) can block Fas Ligand (FasL). Anti-Mouse Fas Ligand Antibody (MFL3) can be used for the researches of cancer and immunology.

hsa-miR-1243 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-3655 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-4761-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-6718-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

RSK2-IN-2 (Compound 25) is a reversible covalent inhibitor of the RPS6KA3 (RSK2) kinase. RSK2-IN-2 is also described to inhibit MSK1, MSK2 and RSK3.

5-(2-Hydroxyethyl)-2’,3’-di-O-toluoyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

Cbl-b-IN-6 (Compound 246) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC₅₀s of 6.7 nM and 5.2 nM, respectively.

VNPP433-3β (Galeterone 3β-imidazole) hydrochloride is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β hydrochloride induces cell apoptosis. VNPP433-3β hydrochloride inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β hydrochloride can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC).

AR Degrader-1 is a molecular glue degrader targeting the androgen receptor (AR). AR Degrader-1 induces androgen receptor degradation by recruiting the DCAF16 E3 ligase substrate receptor, thereby triggering ubiquitination and proteasomal degradation. AR Degrader-1 exhibits relatively selective degradation of the androgen receptor in prostate cancer cells, reducing the levels of only a small number of other proteins. AR Degrader-1 can be used in studies related to prostate cancer.

APL-1091 (Mal-Exo-EEVC-MMAE) is an ADC payload-linker conjugate (Drug-Linker Conjugates for ADC). APL-1091 is formed by the conjugation of the Mal-Exo-EEVC (HY-169353) linker and MMAE (HY-15162), a microtubule inhibitor. APL-1091 resists aggregation at high drug-to-antibody ratio (DAR), exhibits excellent plasma stability, and reduces premature payload release. When conjugated with Trastuzumab (HY-P9907), APL-1091 displays anti-tumor activity in gastric cancer xenograft models. APL-1091 can be used for ADC synthesis and gastric cancer-related research.

Coumestan is a secondary metabolite found in leguminous plants and can be used as drug intermediate Coumestan can be used to synthesize various coumarin compounds such as Coumestrol (HY-N2335), Glytabastan B, and Coumestan Pks13 inhibitor. Coumestans can be used for the study of anti-cancer, anti-inflammatory, anti-oxidative, antibacterial, neuroprotective and organ protective.

hsa-miR-146b-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-5092 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

BIM-46068 is a potent, selectively human brain Farnesyltransferase (FTase) inhibitor (IC₅₀ = 91.4 nM). BIM-46068 can specifically inhibit Ras processing in MiaPaCa-2 cancer cells. BIM-46068 can be used for the study of pancreatic cancer.

HPK1-IN-2 TFA is an orally active HPK1 inhibitor (IC₅₀ < 0.05 µM) with antitumor activity. HPK1-IN-2 TFA inhibits the activity of Lck (IC₅₀ <0.05 µM) and Flt3 (IC₅₀ < 0.05 µM) kinases.